Compare Colgate-Palmolive Company (CL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Vertex Pharmaceuticals Incorporated — how do they compare? Colgate-Palmolive Company trades at $92.43 (market cap $74.26B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Colgate-Palmolive Company pays a 2.28% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| CL | VRTX | |
|---|---|---|
Market Cap | $74.26B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $529.59 |
52-Week Low | $74.98 | $374.46 |
Enterprise Value | $80.74B | $126.92B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.27, up 0.29% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.99, exceeding estimates, driven by strong margins and organic growth in emerging markets, though North American performance remains weak. Operating cash flow remains robust at $4.2 billion in 2025, supporting shareholder returns.
Outlook is mixed: valuation appears stretched with a P/E of 36.72, but analyst consensus targets $99.10. Risks include competitive pressures in North America and high debt levels. The stock offers a stable dividend, but growth concerns and insider selling warrant caution.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
